

## Fund Details

Base Currency	USD
Inception Date	02 December 2022
Domicile	Ireland
Net Assets	USD 5.8M
Shares Outstanding	260,000
Total Expense Ratio	0.55%
Product Structure	Physical (Full Replication)
UCITS Compliant	Yes
Rebalance Frequency	Quarterly
Distribution Frequency	None
Income Treatment	Reinvestment
Swiss Valor	--
ISA Eligibility	Yes
SIPP Available	Yes
Countries of Registration	AT, CH, DE, DK, ES, FI, FR, IE, IT, LU, NL, NO, PL, PT, SE, UK

## Index Information

Index Provider	Market/Vector Indexes
Index Type	Total Return Net
Currency	USD
Inception Date	06 Dec 2021
Rebalance Frequency	Quarterly
Bloomberg Ticker	MVBIONTR
Reuters Ticker	.MVBIONTR

## Fund Data

Number of Holdings	25
Price/Earnings Ratio*	45.94
Price/Book Ratio*	4.70
Weighted Avg. MCap	USD 41.9B

\* Last 12 Months

## Country Breakdown

United States	77.51 %
Switzerland	10.27 %
Italy	2.94 %
Australia	2.71 %
United Kingdom	2.64 %
China	2.05 %
Other/Cash	1.87 %

➤ [www.vaneck.com/ucits/](http://www.vaneck.com/ucits/)

## Fund Description

The VanEck Bionic Engineering UCITS ETF (CYBO) is a UCITS-compliant exchange-traded fund that invests in a portfolio of equity securities with the aim of providing investment returns that closely track the performance of the MVIS<sup>®</sup> Global Bionic Healthcare ESG Index.

The MVIS<sup>®</sup>The MVIS Global Bionic Healthcare ESG Index is a global index that tracks the performance of the largest and most liquid companies in medical/dental or vision-related implants, bioprinting, or prosthesis.

## Performance History\* (%)

Month End as of 30 Apr 2023	1 MO*	3 MO*	YTD*	1 YR	3 YR	5 YR	10 YR	INCEPTION	ETF
MVBIONTR (Index)	5.02	9.15	13.52	4.70	--	--	--	11.28	

Performance quoted represents past performance. Current performance may be lower or higher than average annual returns shown. Discrete performance shows 12 month performance to the most recent Quarter end for each of the last 5yrs where available. E.g. '1st year' shows the most recent of these 12-month periods and '2nd year' shows the previous 12 month period and so on.

Performance data for VanEck ETFs is displayed on a Net Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Brokerage or transaction fees will apply.

## Top 10 Holdings

MEDTRONIC PLC	10.50 %
EDWARDS LIFESCIENCES CORP	10.30 %
STRYKER CORP	10.21 %
DEXCOM INC	9.74 %
ZIMMER BIOMET HOLDINGS INC	7.57 %
SONOVA HOLDING AG	6.12 %
INSULET CORP	4.59 %
STRAUMANN HOLDING AG	4.16 %
INSPIRE MEDICAL SYSTEMS INC	3.40 %
AMPLIFON SPA	2.94 %
SUBTOTAL - TOP 10	69.53 %
REMAINING HOLDINGS	30.29 %
OTHER/CASH	0.18 %
TOTAL	100.00 %

For a complete up-to-date listing of Fund holdings, please visit [www.vaneck.com](http://www.vaneck.com)

**Trading Information**

30 April 2023

EXCHANGE	TRADING CURRENCY	ISIN	EXCHANGE TICKER	BLOOMBERG TICKER	REUTERS TICKER	SEDOL	IOPV SYMBOL
LONDON STOCK EXCHANGE	USD	IE0005TF9619	CYBO	CYBO LN	CYBO.L	BMTPNY4	CYBOUSIV
LONDON STOCK EXCHANGE	GBP	IE0005TF9619	CYBG	CYBG LN	VVCYBG.L	BMTPPH1	--
SIX Swiss Exchange CHF	CHF	IE0005TF9619	CYBO	CYBO SE	CYBO.S	BMTPLL5	--
BORSA ITALIANA	EUR	IE0005TF9619	CYBO	CYBO IM	CYBO.MI	BMTPPK4	CYBOUSIV

Contact us: For more information, call +353 1 485 4989 or visit [www.vaneck.com/ucits/](http://www.vaneck.com/ucits/)

Important Disclosures

For informational and advertising purposes only.

This information originates from VanEck (Europe) GmbH which has been appointed as distributor of VanEck products in Europe by the Management Company VanEck Asset Management B.V., incorporated under Dutch law and registered with the Dutch Authority for the Financial Markets (AFM). VanEck (Europe) GmbH with registered address at Kreuznacher Str. 30, 60486 Frankfurt, Germany, is a financial services provider regulated by the Federal Financial Supervisory Authority in Germany (BaFin). The information is intended only to provide general and preliminary information to investors and shall not be construed as investment, legal or tax advice. VanEck (Europe) GmbH and its associated and affiliated companies (together "VanEck") assume no liability with regards to any investment, divestment or retention decision taken by the investor on the basis of this information. Information herein may change at any time; current data may differ from data quoted. Information provided by third party sources are believed to be reliable and have not been independently verified for accuracy or completeness and cannot be guaranteed. All indices mentioned are measures of common market sectors and performance. It is not possible to invest directly in an index.

VanEck Bionic Engineering UCITS ETF (the "ETF"), a sub-fund of VanEck UCITS ETFs plc, is managed by VanEck Asset Management B.V., registered with the Central Bank of Ireland and tracks an equity index. The value of the ETF assets may fluctuate heavily as a result of the investment strategy. If the underlying index falls in value, the ETF will also lose value.

Investors must read the sales prospectus and key investor information before investing in a fund. These are available in English and the KIDs in certain other languages as applicable and can be obtained free of charge at [www.vaneck.com](http://www.vaneck.com), from the Management Company or from the local information agent details to be found on the website.

MVIS® Global Bionic Healthcare ESG Index is the exclusive property of MarketVector Indexes GmbH (a wholly owned subsidiary of Van Eck Associates Corporation), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MarketVector Indexes GmbH, Solactive AG has no obligation to point out errors in the Index to third parties. The VanEck Bionic Engineering UCITS ETF is not sponsored, endorsed, sold or promoted by MarketVector Indexes GmbH and MarketVector Indexes GmbH makes no representation regarding the advisability of investing in the Fund.

Note: no guarantee can be provided that the fund will attain its objective. Investing is subject to risk, including the possible loss of principal.

No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of VanEck.

The IOPV is calculated by Markit Group Limited.

© VanEck (Europe) GmbH

➤ [www.vaneck.com/ucits/](http://www.vaneck.com/ucits/)